Background
==========

Many types of glomerulonephritis may appear in HIV patients, such as collapsing focal segmental glomerulosclerosis, immune-complex glomerulonephritides, and thrombotic microangiopathy. Immune-complex glomerulonephritides include those associated with HIV (HIV RNA usually over 400 copies/mL), and other types of infectious glomerulonephritis \[[@b1-892641]\].

Leishmaniasis is an important opportunistic infection in HIV, and visceral leishmaniasis (VL) is the most common clinical form.

Renal involvement by leishmania has been well documented in immunocompetent subjects, but in HIV patients the information available is limited \[[@b2-892641]--[@b9-892641]\]. We describe an HIV patient with nephrotic syndrome and membranoproliferative glomerulonephritis (MPGN) associated with VL.

Case Report
===========

A 47-year-old man was admitted for lower-extremity edema of about 3--4 weeks evolution and proteinuria. He had presented hypertension for the previous 18 months, which had been treated with a thiazide and an angiotensin receptor blocker.

He had been diagnosed with HIV infection Stage C3 at another hospital in October 1999 and received antiretroviral treatment. In November 2002 he was diagnosed with VL and treated with antimonials. He was referred to our hospital in October 2004; the patient had ceased receiving the antiretroviral treatment and was asymptomatic, except for nodular skin lesions on the trunk and extremities. A skin biopsy and bone marrow aspiration revealed leishmania, which was treated with antiretrovirals and antimonials. There were several recurrences of leishmaniasis (cutaneous lesions and cytopenias) in the following years, and the patient received liposomal amphotericin B and miltefosine as treatment and prophylaxis.

Physical examination on the current admission to hospital (June 2012) revealed blood pressure 130/80 mm Hg, no fever, edema in the legs up to the knees; other results were normal. The laboratory examinations showed fibrinogen 7.88 g/L, hemoglobin 85 g/L, leukocytes 1.78×10^9^/L, CD4 count 93/μL, platelets 110×10^9^/L, urea 12.5 mmol/L, creatinine 123.76 μmol/L, albumin 19 g/L, GGT 83 U/L, and C-reactive protein 16.7 mg/L; electrolytes, other coagulation parameters, and routine biochemistry results were normal. The following results were normal/negative: immunoglobulins, RF, C3, C4, ANA, anti-DNA, anti-GBM, ANCA, cryoglobulins, and anti-TPO. The blood/urine study for monoclonal proteins was negative. The 24-hour proteinuria was 8 g (high-resolution electrophoresis: non-selective glomerular pattern) and the urine sediment analysis showed 40--60 RBC/HPF. The result of a urine culture was negative. Serology for hepatitis B and C, and HIV RNA PCR and RPR results were negative.

The chest x-ray and ECG findings were normal. Abdominal ultrasound revealed mild splenomegaly and normal kidney size, with increased cortical echogenicity. Bone marrow aspiration showed abundant intra- and extracellular leishmania.

RBCs were transfused, desmopressin was administered, and percutaneous renal biopsy was performed with no technical difficulties (3 needle passes with 3 tissue cores). The glomeruli (9) were of lobular appearance, with diffuse mesangial proliferation and thickened capillary walls with double contours. Leishmania amastigotes were identified in the glomeruli ([Figure 1](#f1-892641){ref-type="fig"}), there were calcium deposits in the interstitium, and the vessels were normal. Immunofluorescence showed mesangial deposits of C3 (+++) and C1q (++); IgG, IgA, IgM, C4, kappa and lambda were negative. These findings were consistent with MPGN.

After the biopsy, the patient presented severe pain in the left lumbar fossa. The CT showed a large left perirenal hematoma; the angiography revealed no bleeding point. RBCs were transfused, tranexamic acid was administered, and the subsequent evolution was positive. The patient was discharged with symptomatic treatment, antiretroviral therapy, interferon-gamma, and Glucantime. He was readmitted a week later with multi-organ dysfunction with involvement of the kidneys (creatinine 654.16 μmol/L), liver, and pancreas; blood cultures and urine culture were negative. Interferon-gamma and/or Glucantime toxicity was considered probable, and was treated with supportive measures and hemodialysis; evolution was satisfactory and renal function improved to a creatinine level of 143.20 μmol/L.

During the subsequent 15 months of follow-up, creatinine remained at 167.96--176.8 μmol/L, proteinuria at 4--6 g/24 hours with normal albumin, CD4 count at 100/μL, HIV RNA at \<50 copies/mL, and PCR for leishmania in the blood was positive. The patient was treated with angiotensin receptor blocker, nifedipine GITS, darbepoetin, allopurinol, omeprazole, oral iron and vitamins, antiretroviral therapy, miltefosine, and liposomal amphotericin B every 15 days.

Discussion
==========

VL in HIV patients is a relapsing disorder characterized by a low cure rate, increased toxicity of anti-leishmania drugs, and the parasite's location in unusual places such as the kidney \[[@b5-892641],[@b9-892641]\]; these characteristics were apparent in this patient.

Leishmania and HIV affect similar immune cells such as macrophages and dendritic cells and have a synergistic effect. Leishmania facilitates the replication and progression of HIV and the virus contributes to the development of VL \[[@b10-892641],[@b11-892641]\]. Both leishmania and HIV alter the Th1/Th2 balance in favor of Th2, and this response facilitates the progression of the parasite \[[@b11-892641]\]. Moreover, leishmania induces chronic activation of the immune system, despite the simultaneous immunosuppression against its antigens, which causes chronic depletion of CD4 T cells and progression of the virus \[[@b11-892641],[@b12-892641]\]. Even in patients like ours, who are receiving antiretroviral treatment and have a low HIV RNA load, there is immune failure that prevents the elimination of leishmania \[[@b13-892641]\].

Glomerulopathy in VL has been associated with immune complex deposition, dependent on the polyclonal activation of B lymphocytes by the parasite. However, studies in animals and humans suggest that other components of the immune system -- macrophages, T cells, and cytokines -- in some cases play a greater role than immune complexes \[[@b12-892641]\]. Leishmania may also be found in the kidney and cause direct local damage \[[@b3-892641]\]. Besides, secondary bacterial skin infection is a frequent complication of cutaneous leishmaniasis. In such cases, the contribution of the bacterial superinfection in the pathogenesis of the glomerulopathy is unclear \[[@b14-892641]\].

[Table 1](#t1-892641){ref-type="table"} shows the cases reported, with details of nephropathy, VL, and HIV. The common findings are CD4 count under 200/μL and an undetectable or positive low-titer HIV RNA. In this patient, the VL was apparent long before the diagnosis of MPGN, but the nephropathy may also be the first manifestation of VL in the HIV infection \[[@b2-892641]\].

In this case, the renal biopsy showed MPGN with mesangial deposits of C3 and C1q. In our patient, negativity for HIV RNA and other parameters (cryoglobulins, hepatitis C and B viruses, monoclonal proteins) and the existence of VL suggest that the latter was linked to the glomerulopathy. The predominance of C3 would suggest a C3 glomerulopathy. However, the presence of dominant or codominant C3 is not uncommon in infectious glomerulonephritis and C1q was also present only in 1 order of magnitude less than C3 \[[@b15-892641]\]. Electron microscopy study would have been helpful, but could not be performed. Moreover, MPGN has been shown to be capable of evolving from a predominance of IgG to a predominance of C3 \[[@b16-892641]\]. However, there remains the possibility that leishmania triggers C3 glomerulopathy in subjects with genetic alterations in the alternative complement pathway.

Two other cases of MPGN, VL, and HIV, in addition to the present one, have been reported. One of them was also affected with the hepatitis C virus, although neither the cryoglobulins nor the immunofluorescence were specified \[[@b8-892641]\]; in the other, hepatitis C and cryoglobulins were negative and the immunofluorescence showed IgG and C3 \[[@b9-892641]\].

The treatment of nephropathy associated with VL in HIV infection is the same as for leishmania. Even if the leishmania is counteracted, the evolution of the nephropathy may be negative \[[@b4-892641]\]. Corticosteroids have been used in immunocompetent patients \[[@b17-892641]\], but to the best of our knowledge, not in cases with HIV coinfection.

Renal biopsy is important for establishing a diagnosis but is of limited therapeutic use in patients with glomerulopathy and HIV/leishmania coinfection. Furthermore, there is an increased risk of hemorrhagic complications in VL, as we found in this case.

Conclusions
===========

In conclusion, VL in HIV infection is a relapsing disease, with difficult therapeutic approach; renal involvement increases the morbidity and mortality of this condition. This case report stresses these important aspects of great relevance in clinical practice.
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###### 

Nephropathy in patients with VL/HIV coinfection.

  **Authors**          **Gender/age**   **CD4 μL**   **HIV RNA c/ml**   **Pathology**                                                              **Clinical manifestations**     **Leishmania in renal biopsy**   **Outcome**
  -------------------- ---------------- ------------ ------------------ -------------------------------------------------------------------------- ------------------------------- -------------------------------- ---------------------------------
  Clevenbergh et al.   M/45             60           \< 200             mesangial hypertrophy, segmental sclerohyalinosis                          ARF, subnephrotic proteinuria   No                               Normalization of renal function
  Rollino et al.       F/28             n.a.         n.a.               focal segmental sclerosis, acute tubulitis, tubular necrosis, vasculitis   ARF                             Yes                              death
  Navarro et al.       M/28             62           \<80               AA amyloidosis                                                             ARF, NS                         No                               HD
  Alexandru et al.     F/42             344          Undetectable       mesangial hyperplasia                                                      NS                              Yes                              Death
  de Vallière et al.   M/32             160--170     Undetectable       AA amyloidosis                                                             ARF, NS                         No                               CRF; NS
  Rybniker et al.      M/49             180--200     Undetectable       extracapillary glomerulonephritis                                          ARF                             No                               HD
  Suankratay et al.    M/37             129          Undetectable       membranoproliferative glomerulonephritis, focal segmental sclerosis        ARF, NS                         No                               Improvement
  Amann et al.         M/45             174          790                membranoproliferative glomerulonephritis                                   ARF, NS                         Yes                              CRF; NS
  Present case         M/47             93           Undetectable       membranoproliferative glomerulonephritis                                   NS                              Yes                              CRF; NP

M -- male; F -- female; n.a. -- not avalaible; ARF -- acute renal failure; NS -- nephrotic syndrome; HD -- hemodialysis; CRF -- chronic renal failure; NP -- nephrotic proteinuria.
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